Plain-English translation of NCT02479698 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called BK-specific cytotoxic T lymphocytes (or BK-CTLs for short) — these are immune cells grown in the laboratory that are designed to recognize and fight BK and JC viruses. The study will give these cells to patients whose immune systems are weakened and who have developed infections from these viruses. Researchers want to see if this approach is safe, feasible, and effective at controlling these hard-to-treat viral infections.
BK and JC viruses can cause serious, life-threatening infections in people with weakened immune systems — such as those with cancer, HIV, or organ transplants — and standard antiviral drugs don't always work. This trial explores whether training immune cells in the lab to specifically target these viruses might offer a new option for patients who haven't responded to other treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive infusions of the specially grown immune cells through an IV over about 30 minutes. You may receive up to 20 infusions total, with at least 2 weeks between each infusion, depending on how you respond and whether you continue to meet eligibility requirements. The study team will monitor you to see how well the treatment works, how long the cells survive in your body, and whether you experience any side effects.
AI-generated summary from trial data · Sep 17, 2026 · Not medical advice
United States